Sign up here to participate at the FEBS 60th Anniversary Symposium arranged by NBS Bergen. The symposium will be held at the third floor of Bygg for Biologiske Basalfag (BBB), Jonas Lies vei 91. Program: 08.30 – 08.45 Coffee and mingling 08.45 - 09.00 Welcoming remarks (Auditorium 4, BBB) 09.00 – 11.00 Science and Innovation Sessions (Audtorium 4, BBB) 11.00 – 12.30 Poster session + Pizza (Vrimlearealet, BBB) 12.30 – 13.30 Key-note lecture from Jan Terje Andersen (Auditorium 1, BBB) _______________________________ Information about the event: Poster session: REUSE YOUR OLD POSTER! Sign up here and bring your old poster for another showing! Everyone is welcome to present, master students, PhDs, researchers and professors alike! There will be pizza, and maybe even a poster prize! Keynote lecture: Jan Terje Andersen Department of Pharmacology, Institute of Clinical Medicine, University of Oslo Department of Immunology, Oslo University Hospital and University of Oslo Precision Immunotherapy Alliance (PRIMA), University of Oslo Co-founder of Authera AS Title: Biology-guided Engineering of Protein-based Technologies Abstract: The pharmacological effect of many protein-based therapeutic agents is limited by brief target exposure due to short plasma half-life. As such, plasma half-life is a commercially competitive differentiator. In fact, IgG antibody-based biologics continue to broaden the therapeutic landscape, having a plasma half-life of about 3 weeks at average in humans. This has made IgG the natural choice for design of antibody therapeutics, while also albumin is increasingly used as a fusion partner as it shares a long plasma half-life with that of IgG. Remarkably, these unrelated proteins engage a common, broadly expressed cellular receptor, FcRn. I will discuss how in-depth insights into the complex structural and cellular mechanisms that govern the functions of FcRn pave the way for design of tailored protein-based biologics and vaccines with improved binding and transport properties relevant for both invasive and non-invasive delivery strategies. Furthermore, I will highlight how we are collaborating with biotech and pharma companies to make it more likely that we succeed with translating our findings into technologies and products for the patients in need. The event is open for all, sign up below! If you have any questions about the event, let us know by sending an email: svein.stove@uib.no We hope to see you there!